Bg pattern

VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Vividrin 0.5 mg/ml eye drops, solution in single-dose container

azelastine hydrochloride

Read this package leaflet carefully before you start using this medicine, because it contains important information for you.

Follow exactly the administration instructions of the medicine contained in this package leaflet or as indicated by your doctor, pharmacist, or nurse.

  • Keep this package leaflet, you may need to read it again.
  • If you need advice or more information, consult your doctor or pharmacist.
  • If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. See section 4.
  • If after 48 hours you do not feel better or worsen, consult your doctor.

Contents of the package leaflet

  1. What is Vividrin and what is it used for
  2. What you need to know before you start using Vividrin
  3. How to use Vividrin
  4. Possible side effects
  5. Storage of Vividrin
  6. Contents of the pack and further information

1. What is Vividrin and what is it used for

This medicine contains azelastine hydrochloride, which belongs to a group of known antihistamines. Antihistamines prevent the effects of substances such as histamine that are produced by the body as part of an allergic reaction. Azelastine has been shown to reduce ocular inflammation.

This medicine is used in the following situations:

  • Treatment and prevention of ocular disorders caused by hay fever (seasonal allergic conjunctivitis) in adults and children from 4 years of age.
  • Treatment of ocular disorders caused by allergy to dust mites or animal hair (perennial allergic conjunctivitis) in adults and children from 12 years of age.

This medicine is notsuitable for the treatment of eye infections.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you start using Vividrin

Do not use Vividrin:

If you are allergic to azelastine hydrochloride or any of the other components of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor or pharmacist before starting to use this medicine:

  • If you are not sure that your eye symptoms are caused by an allergy. In particular, if they only affect one eye, if your vision has worsened, or if you have eye pain and no nasal symptoms, it may be an infection rather than an allergy.
  • If symptoms worsen or last more than 48 hours without noticeable improvement despite using this medicine.
  • If you wear contact lenses.

Children and adolescents

This medicine should not be used in children under 4 years of age for the treatment and prevention of ocular disorders related to hay fever (seasonal allergic conjunctivitis).

This medicine should not be used in children under 12 years of age for the treatment of ocular disorders caused by allergy to dust mites or animal hair (perennial allergic conjunctivitis).

Other medicines and Vividrin

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicine.

It is not known if this medicine can be affected by other medicines.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.

Driving and using machines

You may notice blurred vision for a short period after applying this medicine. If this happens, wait until your vision returns before driving or using machinery.

3. How to use Vividrin

Follow exactly the administration instructions of this medicine contained in this package leaflet or as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again. Remember: this medicine should only be applied to the eyes.

The recommended dose is:

Ocular disorders caused by hay fever (seasonal allergic conjunctivitis)

Use in adults and children from 4 years of age.

The usual dose is one drop in each eye, morning and night.

If you anticipate exposure to pollen, you can take the usual dose of this medicine as a preventive measure before going outside.

Ocular disorders caused by allergy (perennial allergic conjunctivitis)

Use in adults and children from 12 years of age.

The usual dose is one drop in each eye, morning and night.

If your symptoms are severe, your doctor may increase the dose to one drop in each eye up to four times a day.

Relief from allergic conjunctivitis symptoms should be noticed within 15-30 minutes.

Method of administration (application of the eye drops)

To facilitate the correct application of the eye drops, it may be helpful to sit in front of a mirror so you can see what you are doing.

  1. Wash your hands.
  2. Gently clean the contour of your eyes with a cloth to remove any moisture.
  3. Carefully separate a single-dose container from the top of the strip (Fig. 1) and open it. Twist and separate the top of the single-dose unit (without pulling it) (Fig. 2).
  1. Tilt your head back.

Hand holding and breaking ampoule of medicine next to blister pack with several intact ampoulesHands holding a device with a curved tip and inserting it into the skin

Fig. 1 Fig. 2

  1. Gently pull the lower eyelid down.
  2. Place one drop carefully inside the middle area of the lower eyelid. Make sure the container does not touch the eye to avoid contamination (Fig. 3).

Hand holding an eye dropper with liquid medicine over the open eye and lower eyelid

Fig. 3.

  1. Release the lower eyelid and gently press the inner corner of the eye against the bridge of the nose. While the finger presses the nose, blink slowly a few times to spread the drop across the entire surface of the eye.
  2. Wipe away any excess medicine with a cloth.
  3. Repeat the procedure with the other eye.

Duration of treatment

If possible, use this medicine regularly until symptoms have disappeared. If you stop using this medicine, it is likely that your symptoms will recur.

Do not use this medicine for more than 6 weeks.

If you use more Vividrin than you should:

If you accidentally administer too much Vividrin in the eye, it is likely that you will not have any problems. If you have any doubts, consult your doctor. In case of accidental ingestion of this medicine, contact your doctor or go to the emergency department of the nearest hospital immediately.

If you forget to use Vividrin

Use your eye drops as soon as you remember. Apply the next dose at the usual time. Do not apply a double dose to make up for the forgotten dose.

If you stop using Vividrin

If you have any other doubts about using this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Common side effects (may affect up to 1 in 10 people):

Mild irritation (stinging, itching, tearing) in the eyes after using this medicine. These effects should not last long.

Uncommon side effects (may affect up to 1 in 100 people):

Bitter taste in the mouth. This effect should disappear quickly, especially if you take a drink.

Rare side effects (may affect up to 1 in 10,000 people):

Allergic reaction (such as rash and itching).

Reporting side effects

If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Vividrin

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date stated on the carton and on the container, after "EXP".

Use the single-dose container only once.

Medicines should not be disposed of via wastewater or household waste. Return the containers and medicines you no longer need to the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This will help protect the environment.

Do not store above 25°C.

6. Contents of the pack and further information

Composition of Vividrin

  • The active substance is azelastine hydrochloride.

Each milliliter contains 0.5 mg of azelastine hydrochloride.

Each drop contains 0.018 mg of azelastine hydrochloride.

  • The other ingredients are:

Sorbitol 70% solution (non-crystallizing), hypromellose, disodium edetate, sodium hydroxide, and water for injections.

Appearance of Vividrin and contents of the container

This medicine is a colorless and transparent solution presented in a transparent LDPE single-dose container with a volume of 0.6 ml.

Each carton contains 10, 20, 30, or 60 single-dose containers.

Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder:

BAUSCH + LOMB IRELAND LIMITED

3013 Lake Drive

Citywest Business Campus

Dublin 24, D24PPT3

Ireland

Local representative in Spain

Bausch & Lomb S.A.

Avda. Valdelaparra, nº 4

28108 Alcobendas

Madrid, Spain.

Tel: 91 – 657 63 00

Manufacturer:

DR. GERHARD MANN. CHEM.

Brunsbütteler Damm 165/173,

13581 Berlin.

Germany

This medicine is authorized in the Member States of the European Economic Area under the following names:

DE:Vividrin Azelastin EDO 0,5 mg/ml Augentropfen, Lösung im Einzeldosisbehältnis

NL:Azelergo 0,5 mg/ml oogdruppels, oplossing

AT:Vividrin Azelastin EDO 0,5 mg/ml Augentropfen, Lösung im Einzeldosisbehältnis

IT:Monodrin occhi

SI:Alezaxin 0,5 mg/ml kapljice za oko, raztopina v enoodmernem vsebniku

BE:Azelergo 0,5 mg/ml collyre en solution en récipient unidose

LU:Azelergo 0,5 mg/ml collyre en solution en récipient unidose

PT:Vivilin

ES:Vividrin 0,5 mg/ml colirio en solución en envase unidosis

EE:Vividrin

This package leaflet was last revised inMay 2021

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

Online doctors for VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS

Discuss questions about VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS?
VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS?
The active ingredient in VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS is azelastine. This information helps identify medicines with the same composition but different brand names.
How much does VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS cost in pharmacies?
The average pharmacy price for VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS is around 17.61 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS?
VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS is manufactured by Bausch + Lomb Ireland Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to VIVIDRIN 0.5 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS?
Other medicines with the same active substance (azelastine) include AFLUON 0.5 mg/ml EYE DROPS SOLUTION, AZELASTINE ABAMED 0.5 mg/ml EYE DROPS SOLUTION, AZELASTINE MABO 0.5 mg/ml EYE DROPS SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media